Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-3)

A 54 Week, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Acetylcholinesterase Inhibitors on Cognition and Overall Clinical Response in APOE4-stratified Subjects With Mild to Moderate Alzheimer's Disease

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose. RSG XR, the investigational drug used in this study, is an extended-release form of RSG.

This study tests whether RSG XR safely provides clinical benefit to people with mild to moderate Alzheimer's disease (AD) when combined with one of the currently approved AD medications, Aricept®, Razadyne® or Exelon®. RSG XR is a new approach to AD therapy and this study tests a new way to treat AD by testing whether one's genetic makeup affects the response to the study drug. Clinical data suggesting that RSG may benefit AD patients was first seen in a small study performed at the University of Washington and then from a larger GSK study conducted in Europe and New Zealand. In the first study, subjects receiving RSG once daily for 6 months scored significantly better on 3 tests of memory and thought than those who did not receive RSG. In the GSK study, those that appeared to benefit most from treatment with RSG XR had a specific genetic pattern. They did not have the gene that caused them to produce the protein apolipoprotein E e4 (APOE e4). Subjects who have the APOE e4 gene may have two copies, one from each parent, or they may have only one APOE e4 gene meaning that they inherited either the APOE e2 or APOE e3 version of the gene, instead of APOE e4, from one of their parents. Subjects with one copy of the APOE e4 gene remained at their same level of thinking ability while those with two copies of the APOE e4 gene, continued to worsen during the 6-month treatment. The current study will more directly test the effectiveness or RSG XR on people who either have or lack the APOE e4 gene.

Study Overview

• Status: Completed
• Conditions: Alzheimer's Disease
• Intervention / Treatment: Other: Placebo; Drug: Rosiglitazone Extended Release 2mg; Drug: Rosiglitazone Extended Release 8mg

Detailed Description

A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer's disease (REFLECT-3)

• Study Type: Interventional
• Enrollment (Actual): 1468
• Phase: Phase 3

Contacts and Locations

Study Locations

• Australia
  • New South Wales
    • Hornsby, New South Wales, Australia, 2077
      • GSK Investigational Site
    • Randwick, New South Wales, Australia, 2031
      • GSK Investigational Site
  • Queensland
    • Auchenflower, Queensland, Australia, 4066
      • GSK Investigational Site
    • Chermside, Queensland, Australia, 4032
      • GSK Investigational Site
    • Kippa Ring, Queensland, Australia, 4021
      • GSK Investigational Site
  • South Australia
    • Adelaide, South Australia, Australia, 5000
      • GSK Investigational Site
    • Woodville, South Australia, Australia, 5011
      • GSK Investigational Site
  • Victoria
    • Cheltenham, Victoria, Australia, 3192
      • GSK Investigational Site
    • Heidelberg West, Victoria, Australia, 3084
      • GSK Investigational Site
    • Kew, Victoria, Australia, 3101
      • GSK Investigational Site
  • Western Australia
    • Nedlands, Western Australia, Australia, 6009
      • GSK Investigational Site
• Belgium
  • Bruxelles, Belgium, 1070
    • GSK Investigational Site
  • Kortrijk, Belgium, 8500
    • GSK Investigational Site
  • Leuven, Belgium, 3000
    • GSK Investigational Site
  • Woluwe-Saint-Lambert, Belgium, 1200
    • GSK Investigational Site
• Bulgaria
  • Sofia, Bulgaria, 1431
    • GSK Investigational Site
  • Sofia, Bulgaria, 1527
    • GSK Investigational Site
  • Sofia, Bulgaria, 1113
    • GSK Investigational Site
  • Varna, Bulgaria, 9010
    • GSK Investigational Site
• Canada
  • Québec, Canada, G1R 3X5
    • GSK Investigational Site
  • British Columbia
    • Kelowna, British Columbia, Canada, V1W 4V5
      • GSK Investigational Site
  • New Brunswick
    • Saint John, New Brunswick, Canada, E2L 3L6
      • GSK Investigational Site
  • Nova Scotia
    • Kentville, Nova Scotia, Canada, B4N 4K9
      • GSK Investigational Site
  • Ontario
    • Kingston, Ontario, Canada, K7L 5G2
      • GSK Investigational Site
    • Ottawa, Ontario, Canada, K1G 4G3
      • GSK Investigational Site
    • Ottawa, Ontario, Canada, K1N 5C8
      • GSK Investigational Site
    • Peterborough, Ontario, Canada, K9H 2P4
      • GSK Investigational Site
    • Toronto, Ontario, Canada, M6M 3Z5
      • GSK Investigational Site
    • Toronto, Ontario, Canada, M3B 2S7
      • GSK Investigational Site
  • Quebec
    • Greenfield Park, Quebec, Canada, J4V 2J2
      • GSK Investigational Site
    • Mirabel, Quebec, Canada, J7J 2K8
      • GSK Investigational Site
    • Montreal, Quebec, Canada, H4H 1R3
      • GSK Investigational Site
    • Sherbrooke, Quebec, Canada, J1J 3H5
      • GSK Investigational Site
• Czechia
  • Olomouc, Czechia, 775 20
    • GSK Investigational Site
  • Praha 10, Czechia, 10000
    • GSK Investigational Site
  • Praha 8, Czechia, 180 00
    • GSK Investigational Site
  • Trutnov, Czechia, 541 01
    • GSK Investigational Site
• Finland
  • Helsinki, Finland, 00120
    • GSK Investigational Site
  • Joensuu, Finland, 80100
    • GSK Investigational Site
  • Kuopio, Finland, 70211
    • GSK Investigational Site
• France
  • Bordeaux, France, 33076
    • GSK Investigational Site
  • La Chapelle sur Erdre, France, 44240
    • GSK Investigational Site
  • La Seyne sur Mer, France, 83500
    • GSK Investigational Site
  • Lille, France, 59000
    • GSK Investigational Site
  • Limoges, France, 87042
    • GSK Investigational Site
  • Metz, France, 57000
    • GSK Investigational Site
  • Nantes, France, 44300
    • GSK Investigational Site
  • Nantes, France, 44000
    • GSK Investigational Site
  • Paris, France, 75013
    • GSK Investigational Site
  • Sautron, France, 44880
    • GSK Investigational Site
  • Toulon, France, 83000
    • GSK Investigational Site
  • Toulouse, France, 31300
    • GSK Investigational Site
  • Valence, France, 26000
    • GSK Investigational Site
• Germany
  • Berlin, Germany, 13187
    • GSK Investigational Site
  • Berlin, Germany, 13125
    • GSK Investigational Site
  • Berlin, Germany, 10625
    • GSK Investigational Site
  • Berlin, Germany, 12167
    • GSK Investigational Site
  • Berlin, Germany, 12163
    • GSK Investigational Site
  • Berlin, Germany, 13507
    • GSK Investigational Site
  • Berlin, Germany, 13156
    • GSK Investigational Site
  • Berlin, Germany, 13053
    • GSK Investigational Site
  • Berlin, Germany, 12555
    • GSK Investigational Site
  • Berlin, Germany, 13357
    • GSK Investigational Site
  • Berlin, Germany, 13439
    • GSK Investigational Site
  • Berlin, Germany, 14163
    • GSK Investigational Site
  • Baden-Wuerttemberg
    • Aalen, Baden-Wuerttemberg, Germany, 73430
      • GSK Investigational Site
    • Calw, Baden-Wuerttemberg, Germany, 75365
      • GSK Investigational Site
    • Ellwangen, Baden-Wuerttemberg, Germany, 73479
      • GSK Investigational Site
    • Ludwigsburg, Baden-Wuerttemberg, Germany, 71634
      • GSK Investigational Site
    • Stuttgart, Baden-Wuerttemberg, Germany, 70176
      • GSK Investigational Site
    • Tuebingen, Baden-Wuerttemberg, Germany, 72076
      • GSK Investigational Site
    • Ulm, Baden-Wuerttemberg, Germany, 89073
      • GSK Investigational Site
    • Ulm, Baden-Wuerttemberg, Germany, 89075
      • GSK Investigational Site
    • Wiesloch, Baden-Wuerttemberg, Germany, 69168
      • GSK Investigational Site
  • Bayern
    • Alzenau, Bayern, Germany, 63755
      • GSK Investigational Site
    • Muenchen, Bayern, Germany, 81675
      • GSK Investigational Site
    • Unterhaching, Bayern, Germany, 82008
      • GSK Investigational Site
  • Brandenburg
    • Bad Saarow, Brandenburg, Germany, 15526
      • GSK Investigational Site
  • Hessen
    • Bad Homburg, Hessen, Germany, 61348
      • GSK Investigational Site
    • Erbach, Hessen, Germany, 64711
      • GSK Investigational Site
  • Sachsen
    • Chemnitz, Sachsen, Germany, 09111
      • GSK Investigational Site
    • Dresden, Sachsen, Germany, 01307
      • GSK Investigational Site
    • Dresden, Sachsen, Germany, 01097
      • GSK Investigational Site
    • Leipzig, Sachsen, Germany, 04107
      • GSK Investigational Site
    • Leipzig, Sachsen, Germany, 04103
      • GSK Investigational Site
    • Leipzig, Sachsen, Germany, 04157
      • GSK Investigational Site
  • Thueringen
    • Gera, Thueringen, Germany, 07551
      • GSK Investigational Site
    • Jena, Thueringen, Germany, 07743
      • GSK Investigational Site
• Hong Kong
  • Hong Kong, Hong Kong
    • GSK Investigational Site
  • Shatin, Hong Kong
    • GSK Investigational Site
• Korea, Republic of
  • Seongnam-si,, Korea, Republic of, 463-707
    • GSK Investigational Site
  • Seoul, Korea, Republic of, 138-736
    • GSK Investigational Site
  • Seoul, Korea, Republic of, 150-713
    • GSK Investigational Site
• Malaysia
  • Bandar Tun Razak, Cheras, Malaysia, 59100
    • GSK Investigational Site
  • Bandar Tun Razak, Cheras, Malaysia, 50586
    • GSK Investigational Site
  • Ipoh, Malaysia, 30990
    • GSK Investigational Site
  • Kelantan, Malaysia, 16150
    • GSK Investigational Site
• Netherlands
  • Alkmaar, Netherlands, 1815 JD
    • GSK Investigational Site
  • Blaricum, Netherlands, 1261 AN
    • GSK Investigational Site
  • Den Bosch, Netherlands, 5232 JL
    • GSK Investigational Site
  • Den Haag, Netherlands, 2545 CH
    • GSK Investigational Site
  • Hengelo, Netherlands, 7555 DL
    • GSK Investigational Site
  • Hilversum, Netherlands, 1213 XZ
    • GSK Investigational Site
• Philippines
  • Manila, Philippines, 1000
    • GSK Investigational Site
  • Pasig City, Philippines, 1600
    • GSK Investigational Site
• Poland
  • Bydgoszcz, Poland, 85-796
    • GSK Investigational Site
  • Krakow, Poland, 31-530
    • GSK Investigational Site
  • Torun, Poland, 87-100
    • GSK Investigational Site
  • Warsaw, Poland, 02-097
    • GSK Investigational Site
• Singapore
  • Singapore, Singapore, 169608
    • GSK Investigational Site
  • Singapore, Singapore, 308433
    • GSK Investigational Site
  • Singapore, Singapore, 539747
    • GSK Investigational Site
• Slovakia
  • Bratislava, Slovakia, 811 01
    • GSK Investigational Site
  • Bratislava, Slovakia, 811 07
    • GSK Investigational Site
  • Bratislava, Slovakia, 825 56
    • GSK Investigational Site
  • Kosice, Slovakia, 041 66
    • GSK Investigational Site
• Slovenia
  • Ljubljana, Slovenia, 1000
    • GSK Investigational Site
  • Šempeter, Slovenia, 5290
    • GSK Investigational Site
• South Africa
  • Loeventstein, South Africa, 7530
    • GSK Investigational Site
  • Oakdale, South Africa, 7530
    • GSK Investigational Site
  • Richards Bay, South Africa, 3900
    • GSK Investigational Site
  • Rosebank, South Africa, 2196
    • GSK Investigational Site
  • Somerset West, South Africa, 7130
    • GSK Investigational Site
  • Waverley, Bloemfontein, South Africa, 9301
    • GSK Investigational Site
  • Willows, X14, Pretoria, South Africa, 0040
    • GSK Investigational Site
• Spain
  • Baracaldo/Vizcaya, Spain, 48903
    • GSK Investigational Site
  • Barcelona, Spain, 08025
    • GSK Investigational Site
  • Barcelona, Spain, 08036
    • GSK Investigational Site
  • Barcelona, Spain, 08003
    • GSK Investigational Site
  • Barcelona, Spain, 08907
    • GSK Investigational Site
  • Barcelona, Spain, 08014
    • GSK Investigational Site
  • Palma de Mallorca, Spain, 07014
    • GSK Investigational Site
  • Tarrasa, Barcelona, Spain, 08221
    • GSK Investigational Site
• Sweden
  • Falköping, Sweden, SE-521 85
    • GSK Investigational Site
  • Jönköping, Sweden, SE-551 85
    • GSK Investigational Site
  • Kalix, Sweden, SE-952 82
    • GSK Investigational Site
  • Mölndal, Sweden, SE-431 41
    • GSK Investigational Site
  • Sundsvall, Sweden, SE-851 86
    • GSK Investigational Site
  • Umeå, Sweden, SE-901 85
    • GSK Investigational Site
• United Kingdom
  • Bradford, United Kingdom, BD3 0DQ
    • GSK Investigational Site
  • Liverpool, United Kingdom, L9 7LJ
    • GSK Investigational Site
  • Stirling, United Kingdom, FK8 1RW
    • GSK Investigational Site
  • West End, Southampton, United Kingdom, SO30 3JB
    • GSK Investigational Site
  • West of Scotland Science Park, Glasgow, United Kingdom, G20 0XA
    • GSK Investigational Site
  • Lancashire
    • Blackpool, Lancashire, United Kingdom, FY2 0JH
      • GSK Investigational Site
• United States
  • Arizona
    • Sun City, Arizona, United States, 85351
      • GSK Investigational Site
    • Tucson, Arizona, United States, 85741
      • GSK Investigational Site
  • Arkansas
    • Little Rock, Arkansas, United States, 72205
      • GSK Investigational Site
  • California
    • Laguna Hills, California, United States, 92653
      • GSK Investigational Site
    • Redlands, California, United States, 92374
      • GSK Investigational Site
    • San Diego, California, United States, 92103
      • GSK Investigational Site
    • San Francisco, California, United States, 94109
      • GSK Investigational Site
  • Connecticut
    • Norwalk, Connecticut, United States, 06851
      • GSK Investigational Site
  • Florida
    • Deerfield Beach, Florida, United States, 33064
      • GSK Investigational Site
    • Delray Beach, Florida, United States, 33445
      • GSK Investigational Site
    • Fort Lauderdale, Florida, United States, 33308
      • GSK Investigational Site
    • Hialeah, Florida, United States, 33016
      • GSK Investigational Site
    • Ocala, Florida, United States, 34471
      • GSK Investigational Site
    • Saint Petersburg, Florida, United States, 33702
      • GSK Investigational Site
    • Tampa, Florida, United States, 33617
      • GSK Investigational Site
  • Georgia
    • Decatur, Georgia, United States, 30033
      • GSK Investigational Site
  • Illinois
    • Chicago, Illinois, United States, 60610
      • GSK Investigational Site
  • Massachusetts
    • Springfield, Massachusetts, United States, 01104
      • GSK Investigational Site
    • West Yarmouth, Massachusetts, United States, 02673
      • GSK Investigational Site
  • New Jersey
    • Eatontown, New Jersey, United States, 07724
      • GSK Investigational Site
    • Manchester Township, New Jersey, United States, 08759
      • GSK Investigational Site
    • Toms River, New Jersey, United States, 08755
      • GSK Investigational Site
  • New York
    • Amherst, New York, United States, 14226
      • GSK Investigational Site
    • New York, New York, United States, 10032
      • GSK Investigational Site
    • New York, New York, United States, 10016
      • GSK Investigational Site
    • Rochester, New York, United States, 14620
      • GSK Investigational Site
    • Syracuse, New York, United States, 13210
      • GSK Investigational Site
  • North Carolina
    • Raleigh, North Carolina, United States, 27607
      • GSK Investigational Site
    • Winston-Salem, North Carolina, United States, 27103
      • GSK Investigational Site
  • Ohio
    • Centerville, Ohio, United States, 45459
      • GSK Investigational Site
    • Columbus, Ohio, United States, 43210
      • GSK Investigational Site
    • Toledo, Ohio, United States, 43623
      • GSK Investigational Site
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73112
      • GSK Investigational Site
    • Tulsa, Oklahoma, United States, 74104
      • GSK Investigational Site
  • Pennsylvania
    • Jenkintown, Pennsylvania, United States, 19046
      • GSK Investigational Site
    • Norristown, Pennsylvania, United States, 19401
      • GSK Investigational Site
    • Philadelphia, Pennsylvania, United States, 19102
      • GSK Investigational Site
    • Philadelphia, Pennsylvania, United States, 19115
      • GSK Investigational Site
    • Pittsburgh, Pennsylvania, United States, 15213
      • GSK Investigational Site
  • Rhode Island
    • East Providence, Rhode Island, United States, 02914
      • GSK Investigational Site
    • Providence, Rhode Island, United States, 02906
      • GSK Investigational Site
  • South Carolina
    • Greer, South Carolina, United States, 29651
      • GSK Investigational Site
  • Texas
    • San Antonio, Texas, United States, 78229
      • GSK Investigational Site
    • Wichita Falls, Texas, United States, 76309
      • GSK Investigational Site
  • Utah
    • Salt Lake City, Utah, United States, 84107
      • GSK Investigational Site
  • Virginia
    • Charlottesville, Virginia, United States, 22903
      • GSK Investigational Site
  • Washington
    • Seattle, Washington, United States, 98108
      • GSK Investigational Site
  • Wisconsin
    • Middleton, Wisconsin, United States, 53562-2215
      • GSK Investigational Site
    • Milwaukee, Wisconsin, United States, 53226
      • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 50 years to 90 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

A subject will be eligible for inclusion in this study only if all of the following criteria apply:

• Male or female subject with a clinical diagnosis of probable Alzheimer's disease in accordance with NINCDS-ADRDA criteria (Appendix 2).

(Note: National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and Alzheimer's Disease and Related Disorders Association (ADRDA).)

• Subject has mild to moderate Alzheimer's disease as defined by a MMSE score 10 to 26 inclusive at Screening.
• Hachinski Ischemia Score ≤ 4 at Screening (See Appendix 3).
• Age ≥50 and ≤90 years.
• At least 6 months of ongoing acetylcholinesterase inhibitor therapy for Alzheimer's disease, with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study).
• Current use of medication is in accordance with the criteria listed in Table 2 (Permitted Medications, Section 8.1).
• Female subjects must be post-menopausal (i.e. >1 year without menstrual period), surgically sterile, or agree to use adequate method of contraception (Appendix 4) for the duration of the study. Female subjects who are pre-menopausal or who have been post-menopausal for <1 year must undertake pregnancy testing (urine test) at Visit 1, which must be negative.
• Brain CT or MRI scan performed within the past 12 months or at Screening, showing no evidence of any other potential cause of dementia other than Alzheimer's disease.

(Note: Questionable CT or MRI scans should be discussed with the medical monitor, using central imaging guidelines.)

• Neurological exam without focal changes (excluding changes attributable to AD or peripheral trauma).
• Subject has the ability to comply with procedures for cognitive and other testing.
• Subject lives with (or has substantial periods of contact with) a regular caregiver who is willing to attend all visits, oversee the subject's compliance with protocol-specified procedures and study medication, and report on subject's status.

(Note: A non-cohabiting caregiver must spend sufficient time with the subject so that, in the opinion of the Investigator, the caregiver can reliably assess cognitive function, activities and behavior, and report on the subject's compliance and health. As caregiver time spent with a potential subject is anticipated to be highly variable across countries and cultures, GSK will consider a variety of different measures by which this stipulation may be met, and GSK should be consulted if adequacy of a caregiver situation is in doubt. However, as guidance, the ability for a caregiver to meet his/her expected responsibilities for this study would normally be possible when the caregiver spends no less than 10 hours per week with the subject, divided over multiple days.)

• Subject has provided full written informed consent prior to the performance of any protocol-specified procedure; or if unable to provide informed consent due to cognitive status, full written informed consent on behalf of the subject has been provided by a legally acceptable representative.

(Note: Consent by legally acceptable representative is allowed where this is in accordance with local laws, regulations and ethics committee policy.)

• Caregiver has provided full written informed consent on his/her own behalf prior to the performance of any protocol-specified procedure.
• Subjects considered for enrolment must have a QTc (either QTc B (Bazett's correction) or QTc F (Fridericia's correction)) <450msec at Visit 1, with the exception of subjects with bundle branch block (for whom either QTc B or QTc F must be <480msec).

(Note: For the purposes of these criteria, QTc B is defined as (QT interval [msec]) / (square root of RR interval [seconds]); and QTc F is defined as (QT interval [msec]) / (cube root of RR interval [seconds]).)

Exclusion Criteria:

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

• Diagnosis of possible, probable, or definite vascular dementia in accordance with NINDS-AIREN criteria (Appendix 5).

(Note: National Institute of Neurological Disorders and Stroke (NINDS) and Association Internationale pour la Recherche et l'Enseignement en Neurosciences (AIREN).)

• History or evidence of any other CNS disorder that could be interpreted as a cause of dementia: e.g. cerebrovascular disease (stroke, hemorrhage), structural abnormality, epilepsy, infectious or inflammatory/demyelinating CNS conditions, Parkinson's disease.
• Evidence of the following disorders: current vitamin B12 deficiency, positive syphilis serology, or active thyroid dysfunction (particularly that suggestive of hypothyroidism), including abnormally high or low serum levels of thyroid stimulating hormone (TSH), that are clinically significant in the opinion of the investigator.

(Note: Testing is required for each parameter only when no result is available from previous 12 months.)

• History of Type 1 diabetes mellitus or secondary diabetes mellitus.
• Type 2 diabetes mellitus where the subject is being treated with insulin, a PPARγ agonist, or an insulin secretagogue (e.g. a sulfonylurea or glitinide).
• Any patient with an HbA1c ≥8.5%. (See Section 6.3.8.4 for Safety Measures for Enrolled Subjects with Type 2 Diabetes Mellitus.)
• History or clinical/investigational evidence of congestive heart failure defined by the New York Heart Association criteria (Class I to IV cardiac status; Appendix 6).
• History of cardiovascular event within the last 6 months (i.e. intervention, percutaneous coronary intervention, vascular surgery, acute coronary syndrome [non Q-wave myocardial infarction, Q-wave myocardial infarction, unstable angina] or significant arrhythmia; or major intervention (e.g. cardiac surgery or angiography plus stenting) scheduled).
• History of significant psychiatric illness such as schizophrenia or bipolar affective disorder that in the opinion of the Investigator would interfere with participation in the study, major depressive disorder (according to DSM-IV) in the past year, or current active depression requiring initiation of treatment.

(Note: If not currently treated, but active depression is suspected, the Cornell Scale for Depression in Dementia (CSDD, Appendix 7) can be used by the Investigator as a guide for deciding whether a prospective subject requires treatment. If the subject has a CSDD score >7, the Investigator should decide if the subject has depression in need of prescribed medication, and a CSDD >12 is considered a strong indicator that treatment is needed. Subjects will be allowed to re-screen after their depression has been adequately managed for >3 months.)

• History or presence of gastro-intestinal, hepatic, or renal disease or other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs, or any other clinically relevant abnormality, medical or psychiatric condition, which, in the opinion of the Investigator, makes the subject unsuitable for inclusion in the study.
• Clinically significant peripheral edema at the time of screening.
• Current or recent drug or alcohol abuse or dependence (defined by DSM-IV criteria for substance-related disorders), or recent or remote history of the same if that could be a contributing factor to the dementia.
• Systolic blood pressure >165 or <90 mmHg or diastolic blood pressure >95 or <60 mmHg at the time of screening.
• Clinically significant anemia (i.e. hemoglobin <11 g/dL for males or <10 g/dL for females) or presence of hemoglobinopathies which would prevent accurate assessment of HbA1c.
• Abnormal kidney function tests (>1.5 times the upper limit of normal (ULN)).
• ALT, AST, or alkaline phosphatase values >2.5 times the ULN, total bilirubin values >1.5 times the ULN, or history of severe hepatobiliary disease (e.g. hepatitis B or C, or cirrhosis, Child-Pugh Class B/C).

(Note: For subjects with a diagnosis of Gilberts Syndrome and an isolated increase in total bilirubin >1.5 ULN, fractionation should be performed. If all of the following conditions are met, the patient may enter or remain in the study, even if total bilirubin >1.5 ULN:

• an elevated unconjugated (indirect) bilirubin;
• the percentage of direct bilirubin <35%;
• ALT, AST, and alkaline phosphatase <2.5 ULN if subject is in screening (<2.0 ULN for Canadian subjects only), or ≤3 ULN if subject is already randomized into the study)
• History of a bone marrow transplant.
• Subject is unable (with assistance, if appropriate) to take study medication as prescribed throughout the study or is at risk of non-compliance with study medication or procedures.
• Subject is an immediate family member or employee of the participating Investigator, of any of the participating site staff, or of GSK.
• In France, a subject is neither affiliated with nor a beneficiary of a social security category.
• The French subject has participated in any study using an investigational drug during the previous 30 days or 5 half-lives (whichever is longer).
• Cognitive tasks prescribed for cognitive rehabilitation and performed under medical supervision are prohibited for 6 months prior to Screening, as well as for the duration of the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm 1; Rosiglitazone Extended Release 2mg OD	Drug: Rosiglitazone Extended Release 2mg; Rosiglitazone Extended Release 2mg OD
Experimental: Arm 2; Rosiglitazone Extended Release 8mg OD	Drug: Rosiglitazone Extended Release 8mg; Rosiglitazone Extended Release 8mg OD
Placebo Comparator: Arm 3; Placebo	Other: Placebo; Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48, as a Function of APOE ε4 Status in APOE4 Negatives Cohort	The 11-item ADAS-Cog assessed a range of cognitive abilities including memory, comprehension, orientation in time and place and spontaneous speech. Most items were evaluated by tests, but some were dependent on clinician ratings on a five point scale. Scores range from 0 to 70 with higher scores indicating greater dysfunction. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. A hierarchical testing procedure was used to control for statistical tests in the two RSG dose groups and the genetic subgroups.	Baseline (Week 0) and Week 48
Change From Baseline in ADAS-Cog Total Score at Week 48, as a Function of APOE ε4 Status in All Except E4/E4s Cohort	The 11-item ADAS-Cog assessed a range of cognitive abilities including memory, comprehension, orientation in time and place and spontaneous speech. Most items were evaluated by tests, but some were dependent on clinician ratings on a five point scale. Scores range from 0 to 70 with higher scores indicating greater dysfunction. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value a t Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. A hierarchical testing procedure was used to control for statistical tests in the two RSG dose groups and the genetic subgroups.	Baseline (Week 0) and Week 48
Change From Baseline in ADAS-Cog Total Score at Week 48, as a Function of APOE ε4 Status in Full Population Cohort	The 11-item ADAS-Cog assessed a range of cognitive abilities including memory, comprehension, orientation in time and place and spontaneous speech. Most items were evaluated by tests, but some were dependent on clinician ratings on a five point scale. Scores range from 0 to 70 with higher scores indicating greater dysfunction. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value a t Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. A hierarchical testing procedure was used to control for statistical tests in the two RSG dose groups and the genetic subgroups.	Baseline (Week 0) and Week 48
Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score at Week 48, as a Function of APOE ε4 Status in APOE4 Negatives Cohort	The CDR-SB was a validated clinical assessment of global function in patients with AD. Impairment was scored in each of 6 cognitive categories on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2, and severe = 3. The 6 individual category ratings, or "box scores", can be added together to give the CDR-Sum of Boxes which ranges from 0 to 18 (severe impairment). Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value a t Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. Primary inference will be based on the week 48 treatment differences obtained from the MMRM model. A hierarchical testing procedure was used to control for statistical tests in the two RSG dose groups and the genetic subgroups.	Baseline (Week 0) and Week 48
Change From Baseline in CDR-SB Score at Week 48, as a Function of APOE ε4 Status in All Except E4/E4s Cohort	The CDR-SB was a validated clinical assessment of global function in patients with AD. Impairment was scored in each of 6 cognitive categories on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2, and severe = 3. The 6 individual category ratings, or "box scores", can be added together to give the CDR-Sum of Boxes which ranges from 0 to 18 (severe impairment). Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value a t Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. Primary inference will be based on the week 48 treatment differences obtained from the MMRM model. A hierarchical testing procedure was used to control for statistical tests in the two RSG dose groups and the genetic subgroups.	Baseline (Week 0) and Week 48
Change From Baseline in CDR-SB Score at Week 48, as a Function of APOE ε4 Status in Full Population Cohort	The CDR-SB was a validated clinical assessment of global function in patients with AD. Impairment was scored in each of 6 cognitive categories on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2, and severe = 3. The 6 individual category ratings, or "box scores", can be added together to give the CDR-Sum of Boxes which ranges from 0 to 18 (severe impairment). Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value a t Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. Primary inference will be based on the week 48 treatment differences obtained from the MMRM model. A hierarchical testing procedure was used to control for statistical tests in the two RSG dose groups and the genetic subgroups.	Baseline (Week 0) and Week 48

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in ADAS-Cog Total Score at Weeks 8, 16, 24 and 36	The 11-item ADAS-Cog assessed a range of cognitive abilities including memory, comprehension, orientation in time and place and spontaneous speech. Most items were evaluated by tests, but some were dependent on clinician ratings on a five point scale. Scores range from 0 to 70 with higher scores indicating greater dysfunction. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value a t Week 0. It was calculated at Weeks 8, 16, 24 and 36. Full population data was presented.	Baseline (Week 0) and Week 8, 16, 24, 36
Change From Baseline in CDR-SB Score at Weeks 12, 24 and 36	The CDR-SB was a validated clinical assessment of global function in patients with AD. Impairment was scored in each of 6 cognitive categories on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2, and severe = 3. The 6 individual category ratings, or "box scores", can be added together to give the CDR-Sum of Boxes which ranges from 0 to 18 (severe impairment). Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value a t Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. It was calculated at Weeks 12, 24 and 36. Full population data was presented.	Baseline (Week 0) and Week 12, 24, 36
Change From Screening in Mini Mental State Examination (MMSE) Total Score	The MMSE consists of 11 tests of orientation, memory (recent and immediate), concentration, language and praxis. Scores range from 0 to 30, with lower scores indicating greater cognitive impairment. The scale is completed by the investigator, based on the performance of the participant. Change from screening was calculated as value at scheduled time point minus screening value. Baseline was defined as value a t Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. Full population data was presented.	Screening (Week -4) and Week 48
Change From Baseline in Disability Assessment for Dementia (DAD) Total Score	The DAD assessed the ability of a participant to execute basic and instrumental activities of daily living (ADL) and leisure activities. The scale consists of 40 questions assessing basic and instrumental ADLs. This scale assessed a participants' ability to initiate, plan, and perform activities related to hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. Each item was scored as yes: 1, no: 0 and N/A: not applicable. Higher scores indicate less disability with a score of 100 indicating no disability and 0 indicating no functional ability. The percentage score was calculated as (DAD Total score /Total number of applicable items) multiplied by 100. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0. Full population data was presented.	Baseline (Week 0) and Week 8, 16, 24, 48
Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score	NPI is an assessment of frequency and severity of behavioral disturbances in dementia that comprised of 10 dimensions: delusions, hallucinations, dysphoria, apathy, euphoria, disinhibition, aggressiveness and agitation, irritability, anxiety, aberrant motor activity. Participant's caregiver asked about behavior in participant. If "Yes", informant then rated both severity on a 3-point scale, 1-mild to 3-severe (total range: 0-36) and frequency using a 4-point scale, 1-occasionally to 4-very frequently. Total score was frequency × severity. Distress was scored on 5-point scale, 0-no distress to 5-very severe or extreme. Total NPI score was calculated by adding all domain scores; NPI total score: 0-144 and NPI distress score: 0-60, higher scores indicated more severe behavioral disturbance. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0. Adjusted means were presented. Full population data was presented.	Baseline (Week 0) and Week 8, 16, 24, 48
Change From Baseline in Domains of the Resource Utilization in Dementia Scale (RUD)- Q1 and Q2 Caregiver Hours	The RUD instrument was developed as a comprehensive tool to assess the amount of resource use among demented patients. RUD assessd both formal and informal resource use of the patient and the primary caregiver, making it possible to calculate costs from a societal perspective. Q1 corresponds to the number of hours during the last month the caregiver spent assisting the patient with toilet visits, eating, dressing, grooming, walking and bathing and Q2 corresponds to the number of hours during the last month the caregiver spent assisting the patient with shopping, food preparation, housekeeping, laundry, transportation, taking medication and managing financial matters. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. Full population data was presented.	Baseline (Week 0) and Week 12, 24, 36, 48
Change From Baseline in European Quality of Life -5 Dimensions (EQ-5D) Scale Total Score- Thermometer Score	The EQ-5D Proxy is an assessment of quality of life and utility benefit. The EQ-5D Proxy is composed of two parts: part two is the visual analogue scale 'Thermometer'. Caregivers are asked to respond as they feel the participant would on dimensions of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 'Thermometer' has endpoints of 100 (best imaginable health state) and 0 (worst imaginable health state). Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value a t Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. Full population data was presented.	Baseline (Week 0) and Week 12, 36, 48
Change From Baseline in EQ-5D Scale Total Score- Utility Score	The EQ-5D Proxy is an assessment of quality of life and utility benefit. The EQ-5D Proxy is composed of two parts: part one is the five dimensional Health State Classification. The Utility score is a caregiver rating of health status on dimensions of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Answers to each question were responded to on a 3-point scale which indicates the level of impairment (level 1= no problem; level 2=some or moderate problem(s) and level 3=unable, or extreme problem with higher scores indicating greater dysfunction. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value a t Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. Full population data was presented.	Baseline (Week 0) and Week 12, 36, 48
Change From Baseline in Alzheimer's Carer's Quality of Life Instrument (ACQLI) Score	The ACQLI is an assessment of caregiver quality of life. This instrument consisted of 30 questions exploring various aspects of carer's quality of life. Each of the questions had two point response, and the 30 questions were summed to provide a total score. Items were assumed to be unidimensional (i.e., represent a single variable) and were scored 0/1 (false/true) before summation into a total score with a 0-30 range. To ease comparisons between scales, ACQLI scores were transformed to range between 0-100 (100: worse). Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value a t Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented. Full population data was presented.	Baseline (Week 0) and Week 12, 36, 48
Change in ADAS-Cog Total Score for Observed Cases at Week 54 Compared to Week 48	The 11-item ADAS-Cog assessed a range of cognitive abilities including memory, comprehension, orientation in time and place and spontaneous speech. Most items were evaluated by tests, but some were dependent on clinician ratings on a five point scale. Scores range from 0 to 70 with higher scores indicating greater dysfunction. It was of interest to compare the single blind phase data between the treatment groups defined based on the double blind treatment group. This analysis only included participants who received at least one dose of single-blind medication. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0. Full population data was presented.	Week 48 and Week 54
Change in CDR-SB Total Score for Observed Cases at Week 54 Compared to Week 48	The CDR-SB was a validated clinical assessment of global function in participants with AD. Impairment was scored in each of 6 cognitive categories on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2, and severe = 3. The 6 individual category ratings, or "box scores", can be added together to give the CDR-Sum of Boxes which ranges from 0 to 18 (severe impairment). It was of interest to compare the single blind phase data between the treatment groups defined based on the double blind treatment group. This analysis only included participants who received at least one dose of single-blind medication. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0. Full population data was presented.	Week 48 and Week 54
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 48	Blood samples were collected for assessments of HbA1c levels at Baseline and up to Week 48. Change from Baseline was calculated as value at scheduled time point minus Baseline value . Baseline was defined as value at Week 0. Endpoint treatment differences which were adjusted to take account of missing data are derived. Full population data was presented.	Baseline (Week 0) and Week 48
Number of Participants With On-treatment Adverse Events (AEs), Serious Adverse Events (SAEs) and Severity of AEs	AE was defined as any untoward medical occurrence in a participant temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE was any untoward medical occurrence that, at any dose results in death, was life threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect or was considered as medically significant.	Upto Week 48
Number of Participants With Change From Baseline in Vital Signs of Clinical Concern at Any Time on Treatment- Weight	Body weight was measured at all visits, without shoes and wearing light clothing. The assessment was performed a t Baseline and up to Week 54. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0. Full population data was presented.	Upto Week 54
Number of Participants With Change From Baseline in Vital Signs of Clinical Concern at Any Time on Treatment- Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)	SBP and DBP of participants were recorded in sitting posture as vital sign at each visit. The blood pressure (BP) values were identified as of potential clinical concern if the values were out of the reference range (for SBP, 90 to 140 mmHg and DBP, 50 to 90 mmHg) or meet a change from baseline criterion. The change from baseline criterion for SBP, was increase from Baseline (high) if increased by more than or equal to (>=) 40 mm Hg from Baseline; decrease from Baseline (low) if decreased by >= 30 mmHg from Baseline. For DBP, increase from baseline (high) if increased by >=30 mmHg from baseline; decrease from Baseline (low) if decreased by >= 20 mmHg from Baseline. Baseline was defined as value at Week 0.	Upto Week 54
Number of Participants With Change From Baseline in Vital Signs of Clinical Concern at Any Time on Treatment- Heart Rate (HR)	HR of participants were recorded in sitting posture as vital sign at each visit. The HR values were identified as of potential clinical concern if the values were out of the reference range (50 to 100 beats per minute) or meet a change from baseline criterion. The change from baseline criterion for HR, was increase from Baseline (high) if increased by more than or equal to (>=) 30 from Baseline; decrease from Baseline (low) if decreased by >= 30 from Baseline. Baseline was defined as value at Week 0. Full population data was presented.	Upto Week 54
Change From Baseline in Weight	Body weight was measured at all visits, without shoes and wearing light clothing. The assessment was performed at Baseline, Weeks 4, 8, 12, 16, 24, 36, 48, 54. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0. Full population data was presented.	Baseline (Week 0) and Weeks 4, 8, 12, 16, 24, 36, 48, 54
Change From Baseline in Hemoglobin	Hematology parameters were assessed at Baseline, Weeks 4, 16, 36, 48. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0. Full population data was presented.	Baseline (Week 0) and Weeks 4, 16, 36, 48
Change From Baseline in Hematocrit	Hematology parameters were assessed at Baseline and up to Week 48. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0.	Baseline (Week 0) and Weeks 4, 16, 36, 48
Any Time on Treatment Differences in Frequencies of Hematology Data Outside the Reference Range	Haematology parameters were identified as of PCC (high [H], low [L]), if the values were out of the reference range (RR). The range for parameters was: platelet (100AV-500AV), red blood cell (RBC , 0.8-1.2), hemoglobin (L: female [F]:10, male [M]:11; H: F:16.5-AV, M:18), hematocrit (0.8-1.2), white blood cell (WBC, 3-15), Total neutrophils (ANC- absolute Neutrophil count) (0.75-1.5), lymphocytes (0.75-1.5), monocyte s (0.75-2), eosinophils (none -2), basophils (none -2), mean corpuscle volume (MCV, 0.8-1.2), mean corpuscular hemoglobin (MCH, 0.8-1.2), mean corpuscular hemoglobin concentration (MCHC , 0.8-1.2), red cell distribution width (RDW, 0.8-1.2), Neutrophil bands (none-1) and segmented neutrophils (0.75-1.3). Full population data was presented.	Up to Week 48
Any Time on Treatment Differences in Frequencies of Clinical Chemistry Data Outside the Reference Range	Clinical chemistry parameters were identified as of PCC (High, Low), if values were out of RR: Alanine amino transferase (ALT,none-120 [250percent upper limit of RR, ULRR ]),Album in (0.75-2),Aldolase(1.1-1.1),Aspartate amino transferase (AST,none-105 (3-64y),137.5(65+y),>250 percent ULRR), Alkaline phosphatase(ALP,none-312.5 (20+y),>250percent ULRR),blood urea nitrogen(BUN)/Creatinine ratio(none-1.25),BUN(none-11),Chloride(80-115),Calcium (0.75-1.25),Carbon dioxide(CO2,15-40) content,Creatinine (22,<50percent lower limit of RR [LLRR ]-155, >125percent ULRR),Creatine phosphokinase(CPK,none-1.25),Gamma glutamyl transferase(GGT,none-2.5),Glucose (3.6-7.8),HbA1C, High density lipoprotein (HDL,0.65-none),Lactate dehydrogenase (LDH,none -2), Low density lipoprotein(LDL,none-1.25),Magnesium (0.5-2),Potassium (3-5.5),Phosphorus inorganic(0.5-1.5), Sodium (130-150), Total protein (0.8-1.5),Total cholesterol(none -1.5),Direct Billirubin.	Upto Week 48
Changes From Baseline in Electrocardiogram (ECG) Parameters- HR	Triplicate 12-lead ECG measures was obtained digitally, approximately one minute apart after the participant had rested in the supine position in a quiet room (no TV, minimal talking) for atleast 10 minutes. The ECG parameters includes HR. The assessments were performed at Baseline and up to Week 54. Change from Baseline was calculated as value at scheduled time point minus Baseline value . Baseline was defined as value at Week 0. Full population data was presented.	Baseline (Week 0) and Weeks 4, 8, 16, 24, 36, 48, 54
Changes From Baseline in ECG Parameters- RR Interval, QT Interval, QTcB, QTcF, PR Interval and QRS Duration	Triplicate 12-lead ECG measures was obtained digitally, approximately one minute apart after the participant had rested in the supine position in a quiet room (no TV, minimal talking) for atleast 10 minutes. The ECG parameters includes PR interval, QRS duration, QT - uncorrected interval, QTc Bazett (QTcB), QTc Fridericia (QTcF) and RR interval. The assessments were performed at Baseline and up to Week 54. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0. Full population data was presented.	Baseline (Week 0) and Weeks 4, 8, 16, 24, 36, 48, 54
Change From Baseline in HbA1c up to Week 54	Blood samples were collected for assessments of HbA1c levels at Baseline, Weeks 12, 24, 36, 48, 54. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value at Week 0.	Baseline (Week 0) and Weeks 12, 24, 36, 48, 54
Change From Baseline in Short Term Memory Assessment	The 11-item ADAS-Cog assessed a range of cognitive abilities including memory, comprehension, orientation in time and place and spontaneous speech. Most items were evaluated by tests, but some were dependent on clinician ratings on a five point scale. Scores range from 0 to 70 with higher scores indicating greater dysfunction. Questions 1 (word recall) and 7 (word recognition) of ADAS-Cog questionnaire was summed to get a short term memory assessment. The score for Question 1 was calculated as the mean number of words not recalled over the trials for which data was available. If data for all three trials was missing, or if the score for Question 7 was missing then the short term memory score will also be set to missing. Change from Baseline was calculated as value at scheduled time point minus Baseline value. Baseline was defined as value a t Week 0. Estimated value was calculated by Active treatment minus Placebo. The adjusted means were presented.	Baseline (Week 0) and upto Week 48

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Publications and helpful links

General Publications

• Harrington C, Sawchak S, Chiang C, Davies J, Donovan C, Saunders AM, Irizarry M, Jeter B, Zvartau-Hind M, van Dyck CH, Gold M. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. Curr Alzheimer Res. 2011 Aug;8(5):592-606. doi: 10.2174/156720511796391935.

Helpful Links

• Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.

Study record dates

Study Major Dates

• Study Start (Actual): July 12, 2006
• Primary Completion (Actual): March 20, 2009
• Study Completion (Actual): March 20, 2009

Study Registration Dates

• First Submitted: June 30, 2006
• First Submitted That Met QC Criteria: June 30, 2006
• First Posted (Estimate): July 4, 2006

Study Record Updates

• Last Update Posted (Actual): September 5, 2017
• Last Update Submitted That Met QC Criteria: August 3, 2017
• Last Verified: August 1, 2017

More Information

Terms related to this study

• Keywords: Alzheimer's disease; cognition; moderate; apolipoprotein E; adjunctive therapy; mild; rosiglitazone
• Additional Relevant MeSH Terms: Mental Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurocognitive Disorders; Neurodegenerative Diseases; Dementia; Tauopathies; Alzheimer Disease; Hypoglycemic Agents; Physiological Effects of Drugs; Rosiglitazone
• Other Study ID Numbers: AVA102670

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Study Data/Documents

1. Dataset Specification
   Information identifier: AVA102670
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
2. Statistical Analysis Plan
   Information identifier: AVA102670
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
3. Individual Participant Data Set
   Information identifier: AVA102670
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
4. Informed Consent Form
   Information identifier: AVA102670
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
5. Study Protocol
   Information identifier: AVA102670
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
6. Clinical Study Report
   Information identifier: AVA102670
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register
7. Annotated Case Report Form
   Information identifier: AVA102670
   Information comments: For additional information about this study please refer to the GSK Clinical Study Register